Evaluation of the mutagenicity of miokamycin (MOM), a new macrolide antibiotic in the Ames Salmonella test and the dominant lethal assay.
Miokamycin (MOM), a new macrolide antibiotic, was tested for mutagenicity in the Ames Salmonella test and the dominant lethal assay. MOM was not mutagenic against S. typhimurium strains TA1535-1538, TA100 and TA98 both with and without activation by S-9 mix. No increases in the frequencies of induced dominant lethal effects were found in MOM treated mice. MOM did not have mutagenic activities on either system.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D005260:Female; D007933:Leucomycins; D008297:Male; D051379:Mice; D015644:Miocamycin; D009152:Mutagenicity Tests; D009153:Mutagens; D012486:Salmonella typhimurium / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D007933:Leucomycins; D009153:Mutagens; D015644:Miocamycin